Galapagos NV ended 2020 with a strong balance sheet but a reconfigured pipeline following its decision, together with partner Gilead Sciences Inc, to abandon plans to pursue a US marketing authorisation for Jyseleca (filgotinib), its small molecule drug for rheumatoid arthritis. The Food and Drug Administration turned back the application in August because of concerns about its benefit/risk profile at a dose of 200 mg. The two companies dropped plans for a US filing in December. The same drug was approved in the EU and Japan however.
